Ophthalmology Book

http://www.fpnotebook.com/

Intraocular Prostaglandin

Aka: Intraocular Prostaglandin, Latanoprost, Xalatan, Bimatoprost, Lumigan, Travoprost, Travatan, Unoprostone, Rescula
  1. Indication
    1. First line agent for Open Angle Glaucoma
  2. Mechanism
    1. Prostaglandin analogs that increase aqueous outflow
  3. Agents
    1. Latanoprost (Xalatan) 0.005% one drop qd
    2. Bimatoprost (Lumigan) 0.030% one drop qd
    3. Travoprost (Travatan) 0.004% one drop qd
    4. Unoprostone (Rescula) 0.150% one drop bid
  4. Efficacy: Latanoprost
    1. Highly effective, low side effect agent
    2. Currently most prescribed Glaucoma agent worldwide
    3. References
      1. Hedman (2000) Eur J Ophthalmol 10:95-104
  5. Adverse Effects
    1. Increased eyelash growth or pigmentation
    2. Altered iris pigmentation

UNOPROSTONE (C0772319)

Concepts Eicosanoid (T111) , Pharmacologic Substance (T121) , Hormone (T125)
English UNOPROSTONE, unoprostone, Unoprostone
Sources
Derived from the NIH UMLS (Unified Medical Language System)


travoprost (C0937916)

Definition (NCI) A synthetic lipophilic isopropyl ester prodrug of the active compound travoprost free acid, a prostaglandin F2alpha analog with anti-glaucoma property. Upon administration, travoprost is hydrolysed to a free acid by corneal esterases, and then selectively stimulating the prostaglandin F (FP prostanoid) receptor, thereby increasing the uveoscleral outflow which leads to a reduction in intra-ocular pressure.
Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH C438103
SnomedCT 391664000, 129493000
English TRAVOPROST @ @ UNIDENTIFIED, TRAVOPROST UNIDENTIFIED, 5-Heptenoic Acid, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethyl Ester,(5Z)-, travoprost (ophthalmic) (medication), travoprost (ophthalmic), travoprost [Chemical/Ingredient], TRAVOPROST, travoprost, travoprost ophthalmic, Travoprost (product), Travoprost (substance), Travoprost
Spanish travoprost (producto), travoprost (sustancia), travoprost
Sources
Derived from the NIH UMLS (Unified Medical Language System)


bimatoprost (C0937917)

Definition (NCI) A synthetic prostamide and structural prostaglandin analogue with ocular hypotensive activity. Bimatoprost mimics the effects of the endogenous prostamides and reduces intraocular pressure by increasing outflow of aqueous humor through both the pressure-sensitive outflow pathway (the trabecular meshwork), and the pressure-insensitive outflow pathway (the uveoscleral routes). It is not clear whether bimatoprost lowers intraocular pressure by stimulating F-Prostanoid receptors or by acting on specific prostamide receptors.
Definition (NCI) A drug used under the name Latisse to increase the length, thickness, and darkness of eyelashes. It is being studied as a way to increase the growth of eyelashes and eyebrows in patients given chemotherapy for cancer. Bimatoprost is also used under the name Lumigan to treat glaucoma (a build-up of fluid in the eye). It lowers pressure in the eye by increasing the flow of natural eye fluids out of the eye. It is a type of prostaglandin analog.
Definition (NCI) The drug bimatoprost used to treat glaucoma (a build-up of fluid in the eye). It lowers pressure in the eye by increasing the flow of natural eye fluids out of the eye. One drop of Lumigan is put directly in the eye once a day.
Concepts Eicosanoid (T111) , Pharmacologic Substance (T121)
MSH C420823
SnomedCT 129492005, 395300006
English 5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-,(5Z)-, 5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-(1alpha(Z),2beta(1E,3S*),3alpha,5alpha))-, bimatoprost (medication), bimatoprost [Chemical/Ingredient], BIMATOPROST, bimatoprost, Bimatoprost, Bimatoprost (product), Bimatoprost (substance), BIMATOPROST UNIDENTIFIED, BIMATOPROST @ @ UNIDENTIFIED
Spanish bimatoprost (producto), bimatoprost (sustancia), bimatoprost
Sources
Derived from the NIH UMLS (Unified Medical Language System)


latanoprost (C0090306)

Definition (NCI) A prostaglandin F2alpha analogue and a prostanoid selective FP receptor agonist with an ocular hypertensive effect. Latanoprost increases uveoscleral outflow and thereby reduces intraocular pressure.
Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH C072042
SnomedCT 330728002, 108838001, 386926002
English latanoprost, Latanoprost [eye], Latanoprost [eye] (product), latanoprost (ophthalmic) (medication), latanoprost (ophthalmic), latanoprost ophthalmic, latanoprost [Chemical/Ingredient], Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate, LATANOPROST, Latanoprost Ophthalmic, Latanoprost, Latanoprost (product), Latanoprost (substance), Latanoprost [eye] (substance)
Spanish latanoprost (ocular), latanoprost (ocular) (producto), latanoprost (producto), latanoprost (sustancia), latanoprost
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Travatan (C0939506)

Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH C438103
English Travatan, travatan, Alcon brand of travoprost
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Eescula (C0939466)

Concepts Eicosanoid (T111) , Pharmacologic Substance (T121)
MSH C072630
English Eescula, rescula, Rescula, Ciba Vision brand of isopropyl unoprostone, Novartis brand of isopropyl unoprostone
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Xalatan (C0593887)

Concepts Organic Chemical (T109) , Pharmacologic Substance (T121)
MSH C072042
English Pfizer brand of latanoprost, xalatan, Xalatan
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Lumigan (C0939372)

Concepts Eicosanoid (T111) , Pharmacologic Substance (T121)
MSH C420823
English Lumigan, lumigan, Pharm-Allergan brand of bimatoprost, Allergan brand of bimatoprost
Sources
Derived from the NIH UMLS (Unified Medical Language System)


Navigation Tree